<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379663</url>
  </required_header>
  <id_info>
    <org_study_id>2011-11-012</org_study_id>
    <nct_id>NCT02379663</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty</brief_title>
  <official_title>Efficacy and Safety for Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study compares an oral direct factor Xa inhibitor with LMWH for
      thromboprophylaxis in the patients undergoing THA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major wound complication</measure>
    <time_frame>2 weeks</time_frame>
    <description>hematoma : size, site woozing : frequency, amount, dressing change count infection : culture</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">639</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Femur Head Necrosis</condition>
  <condition>Femoral Neck Fractures</condition>
  <arm_group>
    <arm_group_label>Oral direct Factor Xa inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low molecular weight heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban was taken orally in a dosage of 10mg once daily</description>
    <arm_group_label>Oral direct Factor Xa inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin was injected subcutaneously in a dosage of 40mg once daily</description>
    <arm_group_label>Low molecular weight heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>subcutaneous injection of 1 cc of normal saline once daily</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female without childbearing potential aged ≥20 years who were scheduled for
             elective primary THA

        Exclusion Criteria:

          -  recent history of active bleeding or VTE

          -  known genetic disorder associated with bleeding tendency or any condition related with
             an increased risk of bleeding

          -  persistent blood pressure of ≥160mmHg systolic and/or ≥100 mmHg diastolic at baseline

          -  myocardial infarction or cerebrovascular accident within three months of the scheduled
             surgery

          -  major surgery in the prior three months

          -  renal insufficiency with a creatinine clearance &lt;60mL/min , hepatic failure combined
             with coagulopathy, or thrombocytopenia (platelets &lt; 100,000/mm³), or planned
             indwelling epidural catheter for &gt; 6 hours after the end of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Femoral Neck Fractures</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

